Research programme: Ig fusion GAIM dimers - Proclara Biosciences

Drug Profile

Research programme: Ig fusion GAIM dimers - Proclara Biosciences

Alternative Names: NPT-007; NPT-014; NPT-189; NPT-289

Latest Information Update: 24 Mar 2017

Price : $50

At a glance

  • Originator NeuroPhage Pharmaceuticals
  • Developer Proclara Biosciences
  • Class Antidementias; Antiparkinsonians; Neuroprotectants; Neuropsychotherapeutics; Recombinant fusion proteins
  • Mechanism of Action Alpha-synuclein modulators; Amyloid beta-protein modulators; Protein aggregation inhibitors; Tau protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Amyloidosis; Parkinson's disease
  • Research Neurological disorders

Most Recent Events

  • 18 Jul 2017 Proclara Biosciences announces intention to submit IND to the US FDA for the treatment of orphan peripheral amyloidoses in the first half of 2018
  • 10 Mar 2017 Early research in Alzheimer's disease in Australia
  • 10 Mar 2017 Early research in Neurological disorders in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top